Description Many people who have Alzheimer’s also have irregular patterns of sleeping at night and napping during the day. A clinical research study is studying an investigational medication in people with Alzheimer’s disease and sleep problems. Qualified study volunteers may receive: Study medication Study-related medical care Transportation...
Dementia with Lewy Bodies (DLB) affects over 1 million people in the United States. It is caused by the buildup of abnormal protein clusters, known as “Lewy Bodies,” within the brain and is characterized by fluctuations in cognitive ability, particularly alertness and attention. Many dementia...
Most individuals with Parkinson’s disease use levodopa as treatment. It is usually taken in pill form, however long-term usage can lessen the effectiveness of the drug leading to off episodes. In these off episodes, individuals with Parkinson’s suffer from slowness, stiffness and tremors. CVT-301, the medication...
What is Mild Cognitive Impairment (MCI)? Mild Cognitive Impairment is a condition in which a person has memory loss or thinking problems that are worse than those caused by normal aging, but not bad enough to interfere with daily activities. A person with MCI has a...
Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer's disease treated with Donepezil. This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient )...
Description A study to evaluate an investigational drug designed to inhibit receptors that are believed to contribute to migraine attacks. This study lasts up to 55 weeks, in which participants will be screened, go through two phases of treatment and have a follow-up visit. Study Treatment Phase –...
Several treatments are available to help ease Alzheimer’s symptoms; however, none of these existing treatments are capable of slowing the progression of the disease and protecting the brain from further damage. Clinical researches are developing new treatments that may slow the progression of Alzheimer’s. The SUVN-502...
A Randomized, Placebo controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease. (Prodromal AD) This is an 18 month study in which subjects that screen and qualify will go onto the program...